Trial reportAlimentary pharmacology & therapeutics2011
Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study.
Trial report in Alimentary pharmacology & therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00287339 (Chronic Cough and Reflux Disease), which is not on this map. Cited by 59 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chronic Cough and Reflux Disease: A Randomized, Double-Blinded, Placebo Controlled Trial of High Dose Proton Pump Inhibition
Who cites it
59 citing papers in PubMed, 9 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Systematic review and meta-analysis: proton pump inhibitors slightly decrease the severity of chronic cough.Scientific reports · 2024Pooled it
- Meta-analysis of Proton Pump Inhibitors in the Treatment of Pharyngeal Reflux Disease.Computational and mathematical methods in medicine · 2022Pooled it
- ACG Clinical Guidelines: Clinical Use of Esophageal Physiologic Testing.The American journal of gastroenterology · 2020Guideline
- Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report.Chest · 2016Guideline
- A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2016Pooled it
- Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016Pooled it
- Pooled it
- Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report.Chest · 2015Guideline
- Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease.Chest · 2013Pooled it
- Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.World journal of gastroenterology · 2022Trial
- Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial.BMC gastroenterology · 2020Trial
- Trial
- A model combining nocturnal baseline impedance, post-reflux swallow-induced peristaltic wave, and acid exposure time enhances prediction of proton pump inhibitor response for extraesophageal symptoms in a Chinese population.Frontiers in medicine · 2026Article
- Patients Presenting With Reflux Symptoms - Whom to Test and Whom to Treat?The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Validity and Reliability of the Arabic Cough Severity Index.Laryngoscope investigative otolaryngology · 2025Article
- Chinese expert consensus on diagnosis and management of gastroesophageal reflux disease in the elderly (2023).Aging medicine (Milton (N.S.W)) · 2024Article
- Efficacy and tolerability of zinc acetate for treatment of chronic refractory cough: pilot randomised futility trial.ERJ open research · 2023Article
- Chronic cough in adults: recommendations from an Italian intersociety consensus.Aging clinical and experimental research · 2022Review
- WAO-ARIA consensus on chronic cough - Part III: Management strategies in primary and cough-specialty care.The World Allergy Organization journal · 2022Review
- The role of smoking and alcohol in mediating the effect of gastroesophageal reflux disease on lung cancer: A Mendelian randomization study.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCough may be a manifestation of gastro-oesophageal reflux disease (GERD). The utility of acid suppression in GERD-related cough is uncertain.
aimTo assess the impact of high-dose acid suppression with proton pump inhibitors (PPI) on chronic cough in subjects with rare or no heartburn.
methodsSubjects were nonsmokers without history of asthma, with chronic cough for >8 weeks. All subjects underwent a baseline 24-h pH/impedance study, methacholine challenge test and laryngoscopy. Subjects were randomised to either 40 mg of esomeprazole twice daily or placebo for 12 weeks. The primary outcome measure was the Cough-Specific Quality of Life Questionnaire (CQLQ). Secondary outcomes were response on Fisman Cough Severity/Frequency scores and change in laryngeal findings.
resultsForty subjects were randomised (22 PPI, 18 placebo) and completed the study. There was no difference between PPI and placebo in CQLQ (mean improvement 9.8 vs. 5.9 respectively, P = 0.3), or Fisman Cough Severity/Frequency scores. Proportion of patients who improved by >1 s.d. on the CQLQ was 27.8% (five of 18) and 31.8% (seven of 22) in the placebo and PPI groups respectively.
conclusionIn subjects with chronic cough and rare or no heartburn, high-dose proton pump inhibitor does not improve cough-related quality of life or symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.